Can ovulation induction be accelerated in women who have PCOS-related infertility?

**Yes** This study describes a “stair-step” protocol that incorporates early ultrasonography to determine whether clomiphene (Clomid) has been effective at stimulating ovulation in infertile women who have polycystic ovary syndrome (PCOS). If it has not been effective, the dosage of clomiphene is immediately increased, bypassing progestin administration and a withdrawal bleed.

Among women treated with this protocol, 74% ovulated at a clomiphene dosage of 100 or 150 mg, compared with the 35.5% ovulation rate associated with these dosages using the traditional progestin-withdrawal protocol.


**Polycystic ovary syndrome is the most common cause of anovulatory infertility, and expert consensus points to clomiphene as first-line therapy.**

Under the conventional protocol, clomiphene is given early in the follicular phase, with midluteal monitoring for ovulation. If ovulation is not detected, progestin is administered to induce a withdrawal bleed, and the dosage of clomiphene is increased in the next cycle. Under this protocol, the clomiphene regimen can last as long as 90 days.

Hurst and colleagues propose a 28-day dosage-escalation method, relying on earlier ultrasonography to document follicular development and, in its absence, immediately “rechallenging” the patient with a higher dosage of clomiphene (FIGURE, page 22).

They present intriguing data from a small, preliminary case series of 31 subjects who used this stair-step protocol. Seventy-four percent of these women ovulated by the end of the 28-day monitoring period, compared with 34% in 89 days among a historical control group using the traditional protocol.

Although a single stair-step cycle was more expensive than a traditional cycle, it has the potential to be less expensive when the rate of ovulation is taken into account.

**Accelerated regimen may have a number of negatives**

At first glance, what’s not to like about a protocol that increases the likelihood of ovulation with significant savings in time and cost for the patient?

First, there are methodologic concerns when a control group is not studied by means of a randomized, controlled trial—or even at the same center as the treatment arm—but is merely created from published data from a textbook.

Second, the goal of infertility therapy is live birth, not ovulation. Our studies have demonstrated significant differences in fecundity for each successful ovulation using different medications, suggesting that not...
every ovulation is the same. In the study by Hurst and colleagues, fecundity (live birth by ovulation rate) was 13%, compared with 10% using clomiphene in our large, multicenter trial—not much of an improvement, although, admittedly, the study by Hurst and colleagues was underpowered to address this question.

Third, there are concerns about potential adverse effects of the accelerated clomiphene regimen on the patient or fetus. Clomiphene has a prolonged half-life of 5 to 7 days, with some metabolites persisting for months. What are the cumulative effects of such aggressive dosage escalation over such a short period of time?

The current Clomid package insert recommends a maximum dosage of 500 mg/cycle. A nonresponder in the stair-step protocol could consume 1,500 mg of clomiphene over a 20-day period.

Hurst and colleagues do not mention side effects, but it would be reasonable to expect an increased rate of hot flashes or mood changes. And what about more concerning signs such as visual changes?

Although clomiphene has no known human teratogenic effects (it is listed as pregnancy category “X”), the stair-step protocol could theoretically produce higher levels of fetal metabolites during the period of organogenesis, with unknown effects.

References


Does US measurement of cervical length to determine the need for cerclage reduce preterm delivery?

No. This randomized, controlled trial of cervical ultrasonographic (US) scanning versus history to determine the need for cerclage found no reduction in the rate of preterm delivery (i.e., delivery before 34 weeks’ gestation) among high-risk women who underwent US imaging. Women who were offered US surveillance were more likely to receive a cerclage and to spend more time in the hospital than women who had a cerclage placed on the basis of history alone. However, there was no improvement in gestational age at delivery in the group that underwent US scanning.

EXPERT COMMENTARY
John T. Repke, MD, University Professor and Chair, Department of Obstetrics and Gynecology, Penn State University College of Medicine, and Obstetrician-Gynecologist-in-Chief, Milton S. Hershey Medical Center, Hershey, Pa. Dr. Repke serves on the OBG Management Board of Editors.

This methodologically rigorous trial explored the utility of US imaging versus history in establishing the “need” for cervical cerclage. I have deliberately placed the word “need” in quotations because, as yet, the efficacy of cerclage under any circumstances has yet to be definitively established.

In their discussion of the findings, Simcox and colleagues assert that a trial to settle the questions frequently raised in the cerclage debate would require thousands of patients and may not be feasible.

Rigorous trial is impressive, but doesn’t settle key questions
The authors performed an excellent randomized, controlled trial, and their intention-to-treat analysis is laudable. They are also to be congratulated for remaining focused on the primary outcome of delivery before 34 weeks’ gestation. It is notable that the primary outcome was essentially the same in each group, regardless of the treatment, be it 1) US screening and cerclage for cervical length <20 mm or 2) no screening and cerclage for historical indications. I recall a conference on prematurity from the mid-1980s that included, as one of its conclusions, the observation that as many as 70% of patients who have historical “indications” for cerclage will deliver at term in their next pregnancy if left untreated.

Unresolved questions in regard to cervical cerclage include:
- What is the best way to determine who is a candidate?
- What is the best type of cerclage?
- What is the most appropriate outcome to be measured?
- Is there a place in practice for “universal” screening of cervical length?
- What is the true cost (in terms of both dollars and morbidity) of intervention versus no intervention?
- What are the medicolegal implications of each approach?

This study by Simcox and colleagues settles none of these questions.

High-risk women may benefit from US imaging, but the data from this study do not support that conclusion. Nor is the best type of cerclage defined, though there is ample opinion on this topic.

Is 34 weeks’ gestation the appropriate primary outcome? More and more, we read about late preterm or so-called near-term outcomes being less optimal than they once were thought to be—though delivery at 34 to 37 weeks would seem to be preferable to delivery at less than 34 weeks.

The cost of each approach is unclear. How many “unnecessary” cerclages would be needed to prevent one very-low-birthweight delivery? And how “risky” is elective cerclage placement in skilled hands?

Finally, not many patients or physicians are likely to want to embrace a wait-and-see approach if they have already had one or more adverse outcomes, and the risk of doing nothing may be considerably greater in medicolegal terms than the risk of proceeding with what may be an unnecessary intervention that ends in a term or near-term delivery.

WHAT THIS EVIDENCE MEANS FOR PRACTICE
On the basis of these results, I think the practitioner should rely on history to make a clinical judgment about the need for cerclage. Ultrasonographic imaging may not only be of little help, but it may lead to greater intervention than would otherwise be needed. Perhaps a return to clinical basics, such as detailed history taking and physical examination, is a good message for these economic times.

JOHN T. REPKE, MD